Proton Pump Inhibitors (PPIs) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Proton Pump Inhibitors (PPIs) Market Forecast 2024-2028

The proton pump inhibitors (PPIs) market size is estimated to grow by USD 807.89 million at a CAGR of 4.86% between 2023 and 2028. Ensuring the appropriate use of medications such as proton pump inhibitors (PPIs), antibiotics, and glucocorticoids is crucial for effective treatment. Since the introduction of the first PPI, omeprazole, in the 1980s, these drugs have been recognized as valuable therapeutic options for addressing acid-related ailments such as gastroesophageal reflux disease, H. pylori eradication therapy, peptic ulcers, stress ulcers, and dyspepsia. Research indicates a significant prevalence of PPI prescriptions in both inpatient and outpatient visits. Several factors contribute to the extensive utilization of these drugs, including the high incidence of acid-related disorders, their proven efficacy and low toxicity, increased availability and affordability of generic PPIs, over-the-counter availability, and consumer-oriented marketing efforts. These factors are poised to propel market growth in the forecast period.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Proton Pump Inhibitors (PPIs) Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

Product Analysis 

OTC PPIs

The market share growth by the OTC PPIs segment will be significant during the forecast period.  Over-the-counter (OTC) drugs are defined as medicines that are sold directly to patients or consumers without a prescription from a healthcare professional. The high proton pump inhibitors market share is attributed to the easy accessibility and affordability of OTC drugs, which increases their use among patients.

Get a glance at the market contribution of various segments Download PDF Sample

The OTC PPIs segment was the largest and was valued at USD 1.40 billion in 2018. According to the US Food and Drug Administration (FDA), these are intended to be used for 14 days and can be used thrice a year. Heartburn is characterized by the backflow of stomach content into the oesophagus, a muscular tube that carries food and liquid from the mouth to the stomach.  The market has witnessed a shift from prescription these to these in the past few years. The availability of these provides patients with an option for self-medication and reduces the financial burden associated with medication treatment by mitigating the need for a prescription for the purchase of these drugs. These factors will drive the growth of the segment of the market during the forecast period.

Route Of Administration Analysis 

Oral

Oral administration stands as a cornerstone in the treatment of infections, offering a convenient and effective means of delivering antibacterial drugs to patients. This route involves the ingestion of PPIs in the form of tablets, capsules, or liquids, allowing the drug to be absorbed through the digestive system and then enter the bloodstream. Oral PPIs are particularly well-suited for less severe infections that do not require immediate intervention or hospitalization. They empower patients to manage their treatment from the comfort of their homes, contributing to outpatient care and reducing the burden on healthcare facilities. Thus, such wide benefits of oral administration will drive the growth of the global market in the oral segment during the forecast period.

Injectable

Intravenous (IV) administration of PPIs plays a pivotal role in the treatment of severe infections, critical medical conditions, and situations where rapid and precise drug delivery is paramount. This route involves injecting medicine directly into the bloodstream through a vein, allowing for immediate distribution throughout the body. Injectable are particularly valuable in hospital settings, where patients require intensive care and continuous monitoring or cannot tolerate oral medications. These are administered intravenously in the following cases: The infection is severe, and other routes may not work well. Antibiotics cannot be taken orally due to vomiting. The types of intravenous administration are as follows: An intravenous injection is an injection given over a few seconds or a few minutes. Intravenous injection is sometimes called a bolus injection. Reduction of gastric acid production can be treated through a brief course of intravenous PPIs. Thus, the increasing incidence of gastrointestinal problems will accelerate the growth of the market in the injectable segment during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The largest proton pump inhibitors market share of the region is attributed to the presence of large pharmaceutical companies that offer both branded and generic and the presence of a proper regulatory framework for the approval of new drugs in the region. In addition, the region also harbours a large patient pool with acid-related problems and requires PPI intervention for their treatment. The increased consumption of alcohol and tobacco and the adoption of an urban lifestyle are the major factors that are contributing to the increased patient pool with gastrointestinal diseases, thus driving the market growth in the region.

Moreover, the increased disposable income of people is leading to a greater number of patients opting for treatment, thereby contributing to the proton pump inhibitors market growth in this region. In addition, the increased focus of key companies on investing in R&D activities to maintain their market position is anticipated to have a positive impact on the market growth during the forecast period. 

Buy Full Report Now

Key Proton Pump Inhibitors (PPIs) Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 19 market companies, including:

Amgen Inc. - The company offers LUMAKRAS with gastric acid reducing agents decreased sotorasib concentrations.

• AstraZeneca Plc
• Aurobindo Pharma Ltd.
• Bausch Health Companies Inc.
• Bayer AG, Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eisai Co. Ltd
• Eli Lilly and Co.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson
• Perrigo Co. Plc
• Pfizer Inc.
• RedHill Biopharma Ltd.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Procter and Gamble Co.
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The growing prevalence of acid-related disorders such as peptic ulcers and gastroesophageal reflux disease (GERD) is a key driver for the Proton Pump Inhibitors (PPIs) market. PPIs are widely recognized and prescribed medications for managing these conditions by reducing excessive stomach acid production, alleviating symptoms like heartburn, and promoting the healing of ulcers. Additionally, lifestyle factors such as obesity, smoking, alcohol consumption, and dietary habits contribute to the increasing incidence of acid-related disorders, further fueling the demand for PPIs.

Moreover, the availability of PPIs as both prescription-only drugs and over-the-counter (OTC) medications expands their accessibility to a broader population, enhancing market penetration. Regulatory agencies like the Subject Matter Expert Committee (SEC) and CDSCO play a significant role in ensuring the safety and efficacy of PPIs, thereby instilling confidence among healthcare providers and patients.

A notable trend in the PPIs market is the integration of artificial intelligence (AI) and big data analytics in drug development and personalized treatment approaches. AI algorithms and analytics enable pharmaceutical companies to streamline drug discovery processes, identify novel drug delivery systems, and optimize treatment regimens based on individual patient characteristics and responses. This trend is poised to revolutionize the PPIs market by enhancing treatment efficacy, reducing adverse effects, and improving patient outcomes.

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

Reformulation of drugs is a key factor driving the market growth. Drug delivery systems such as transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing patient compliance or by increasing the bioavailability of the drug. The reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market. Moreover, the reformulation of solid dosage forms, such as tablets, can provide a window for titrating the dose as per individual requirements. For instance, the availability of two dosage forms, NEXIUM 10 mg and 20 mg, will increase the consumption of the drug for various indications, particularly acid-related diseases, in both children aged one year and above the older patients with difficulty in swallowing. In Japan, AstraZeneca is responsible for manufacturing, while DAIICHI SANKYO is responsible for distribution and sales of NEXIUM 10 mg and 20 mg, thus resulting in the co-promotion of the drug by the two companies.

Further, Eisai is responsible for marketing and manufacturing the drugs, while EA Pharma is responsible for their distribution and sales in Japan Hence, the reformulation of drugs provides companies with patent extension exclusivity and helps them maintain their position in the global market. Therefore, these factors will drive the growth of the global market during the forecast period.

Significant Market Trends

The rising prevalence of obesity is an emerging trend shaping the market growth. The current epidemiology data of obesity and GERD-related disorders such as oesophagal erosions, Barret's oesophagus (BE), and oesophagal adenocarcinoma generated significant curiosity among researchers to study the association between these two conditions. The results from several case-control and cohort studies indicate that obesity fulfills several criteria that establish an association with GERD. According to the World Obesity Federation's World Obesity Atlas 2023, if preventive and treatment strategies do not improve, the yearly worldwide economic cost of overweight and obesity is expected to reach USD 4.32 trillion by 2035. 

However, the rising prevalence of obesity increases the risk of being affected by oesophagal- and gastrointestinal-related diseases, which is anticipated to increase the demand for their treatment, thereby having a positive impact on the growth of the global market during the forecast period.

Major Market Challenges

Counterfeit drugs are a significant challenge hindering the market growth. The probability of buying counterfeit drugs from the market is high. According to the US FDA, many illegal websites sell unapproved drugs that contain the wrong active ingredients or harmful ingredients, or too much or too little of the active ingredients. The FDA notifies website owners through warning letters that their actions violate the Federal Food, Drug, and Cosmetic Act of the United States and that they are involved in criminal behavior. The consumption of counterfeit drugs can affect the health of the consumer, and their availability in the market can affect the sales of branded drugs. The FDA also electronically reviews all shipments of imported goods that are subject to FDA regulations.

In addition. FDA has quality, safety, and efficacy standards that must be met by imported medications. When it comes to registration, listing, drug applications, drug labeling, and current good manufacturing practices (cGMPs), the FDA confirms compliance with these standards. Additionally, the FDA examines and samples imported goods at random. Thus, the production of counterfeit drugs will decrease, which, in turn, will increase the growth of the global market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market research report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018  to 2028. 

• Product Outlook
  • OTC PPIs
  • Prescription PPIs

• Route Of Administration Outlook
  • Oral
  • Injectable

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest Of World
    • Brazil
    • Argentina
    • Australia 

Market Analyst Overview

The market is witnessing substantial growth driven by factors such as aging populations, unhealthy lifestyles, and the prevalence of gastrointestinal disorders. With medications like esomeprazole and dexlansoprazole modified release targeting acid-related disorders, the market is expanding rapidly. Research and development efforts, including Phase 3 clinical trials, focus on novel drug delivery methods and addressing side effects. Generics play a significant role in market expansion, particularly in hospital pharmacies and retail outlets. The market is also influenced by factors like patent expiry and the availability of both prescription and over-the-counter products. With increasing healthcare investment and a focus on reducing stomach acid production, the global PPIs market continues to evolve to meet the needs of a growing consumer base.

The market is thriving due to rising instances of acid-related disorders such as Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. With medications like esomeprazole and dexlansoprazole addressing symptoms like heartburns, market expansion activities focus on gaining marketing and distribution rights, supported by regulatory approval from the United States Food and Drug Administration (USFDA). Generics play a significant role in offering affordable options in both prescription and over-the-counter (OTC) products available at retail pharmacies. The market is characterized by competitive insights and a focus on the reduction of stomach acid production to enhance gastrointestinal health, catering to the needs of an aging population with unhealthy diets and sedentary lifestyles.

In the realm of digestive health, proton pump inhibitors (PPIs) have emerged as indispensable medications for managing acid-related disorders. From their impact on stomach emptying to their interaction with dietary factors like coffee and fatty foods, PPIs play a crucial role in regulating acid secretion and alleviating symptoms associated with conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. Let's delve into the multifaceted world of PPIs, examining their drug types, market dynamics, and physiological effects on digestion.

Proton pump inhibitors (PPIs) belong to a class of medications designed to inhibit the secretion of gastric acid in the stomach. By targeting the proton pumps responsible for acid production, PPIs effectively reduce the acidity of gastric contents, providing relief from symptoms such as heartburn and acid reflux. Stomach emptying plays a crucial role in the efficacy of PPIs, as their absorption and onset of action are influenced by food intake. While certain dietary factors like coffee consumption may delay stomach emptying and subsequently affect PPI absorption, fatty and fried foods have been shown to stimulate acid secretion, potentially exacerbating symptoms in individuals with acid-related disorders.

Market Dynamics and Product Differentiation is an important aspect to consider while vying for market opportunities. Within the PPI market segment, esomeprazole magnesium trihydrate and Dexilant stand out as leading contenders, each vying for market shares and dominance. Generic products also play a significant role in shaping market dynamics, offering cost-effective alternatives to brand-name medications and driving competition among manufacturers. Market sizes and revenue streams reflect the growing demand for PPIs worldwide, driven by factors such as the increasing prevalence of acid-related disorders and the expanding global population.

As stakeholders navigate the complexities of the global PPI market, strategic considerations extend beyond product lines to encompass market segmentation, pricing strategies, and regulatory compliance. Excessive acid release in the gastric lumen can lead to conditions such as colitis and exacerbate symptoms of GERD and peptic ulcers. While PPIs effectively suppress acid secretion in the stomach, they may also impact acid regulation in the small intestine, potentially influencing digestive processes and nutrient absorption.

While PPIs remain the cornerstone of treatment for acid-related disorders, alternative medications such as H2 blockers offer complementary approaches to managing acid secretion. By targeting histamine receptors in the stomach, H2 blockers provide additional options for individuals who may not respond adequately to PPI therapy. In conclusion, proton pump inhibitors (PPIs) play a vital role in regulating acid secretion and managing symptoms associated with acid-related disorders. From their physiological effects on digestion to their market dynamics and clinical considerations, PPIs represent a multifaceted approach to digestive health management. By understanding the complexities of PPI therapy and its interactions with dietary factors, stakeholders can optimize patient outcomes and drive innovation in the field of gastrointestinal medicine.

Proton Pump Inhibitors (PPIs) Market Scope
Report Coverage	Details
Page number	161
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 4.86%
Market Growth 2024-2028	USD 807.89 million
Market structure	Fragmented
YoY growth 2023-2024(%)	4.31
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 36%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd.
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch